Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical hematoporphyrin photodynamic therapy plus pirarubicin for prevention of NMIBC recurrence
ChiCTR2100046736Phase 4Recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hemoporfin and pirarubicin in bladder cancer (2 arms), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Relapse-Free Survival (RFS). Started Jul 2021; status: recruiting.
02
Drugs
hemoporfinpirarubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2100046736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046736.